Sodium Channel Blockers for Pain: New Opportunities After Vertex’s ‘Watershed’ Moment

Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.

Artelo reports positive first-in-human results for novel non-opioid pain therapy - BioTuesdays

Artelo Biosciences (NASDAQ: ARTL) has announced positive results from its first-in-human study evaluating its novel non-opioid candidate, ART26.12, for the treatment of persistent pain. ART26.12 is the first orally active fatty acid binding protein 5 (FABP5) inhibitor evaluated in humans. By targeting FABP5, ART26.12 modulates endogenous lipid signalling molecules that exert analgesic effects through established pathways, including TRPV1, PPAR a…